Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
post
Last Updated: April 2, 2026, 3:18 am
Author: Getaka|Social: XLinkedIn
Stock Ticker - BSE: 532637 | NSE: MANGALAM

Mangalam Drugs and Organics Ltd: Intrinsic Value & Share Price Analysis

Fair Value

₹46.41Undervalued by 62.84%vs CMP ₹28.50

P/E (15.0) × ROE (4.7%) × BV (₹80.50) × DY (2.00%)

Defaults: P/E=15

₹83.41Undervalued by 192.67%vs CMP ₹28.50
MoS: +65.8% (Strong)Confidence: 50/100 (Moderate)Models: 5 Under, 2 Over
ModelCategoryValueWeightSignal
PE-ROEEarnings₹23.1026%Over (-18.9%)
Graham NumberEarnings₹88.9723%Under (+212.2%)
Net Asset ValueAssets₹80.8910%Under (+183.8%)
EV/EBITDAEnterprise₹268.5713%Under (+842.4%)
Earnings YieldEarnings₹43.7010%Under (+53.3%)
ROCE CapitalReturns₹19.6110%Over (-31.2%)
Revenue MultipleRevenue₹100.488%Under (+252.6%)
Consensus (7 models)₹83.41100%Undervalued
Key Drivers: EPS CAGR -50.2% drags value — could be higher if earnings stabilize. | ROE 4.7% is below cost of equity.

PE-ROE · Graham · EPV · DCF · NAV · EV/EBITDA · DDM · Earnings Yield · ROCE Capital · Revenue Multiple | CoE: 12% · Terminal: 4% · EPS CAGR: -50.2% · Defaults: P/E=15

*Investments are subject to market risks

Investment Snapshot

40
Mangalam Drugs and Organics Ltd scores 40/100 (Weak)
Based on 5 dimensions: health, institutional flow, earnings quality, momentum, and peer comparison
Stock Health51/100 · Moderate
ROCE 8.0% AverageROE 4.7% WeakD/E 0.64 ModerateInterest Coverage 0.0x RiskyProfitable 4/5 years Consistent
Smart Money35/100 · Weak
FII holding stable No changePromoter decreased by 14.66% Caution
Earnings Quality60/100 · Moderate
OPM stable around 8% SteadyWorking capital: 13 days (improving) Efficient
Quarterly Momentum15/100 · Weak
Revenue (4Q): -31% YoY DecliningProfit (4Q): -397% YoY DecliningOPM: -2.5% (down 12.4% YoY) Margin pressure
Industry Rank20/100 · Weak
ROCE 8.0% vs industry 16.4% Below peersROE 4.7% vs industry 15.2% Below peers3Y sales CAGR: -11% Shrinking

Weights: Health 30% · Earnings Quality 25% · Momentum 20% · Industry Rank 15% · Smart Money 10%. Scores are computed from reported financials and recalculated daily. Not investment advice.

Share Price and Basic Stock Data

Last Updated: April 2, 2026, 3:18 am

Market Cap 45.1 Cr.
Current Price 28.5
Intrinsic Value₹83.41
High / Low 95.0/22.7
Stock P/E
Book Value 80.5
Dividend Yield0.00 %
ROCE8.03 %
ROE4.71 %
Face Value 10.0
PEG Ratio0.00

Stock P/E, Current Price, and Intrinsic Value Over Time

View Share Price Target for Mangalam Drugs and Organics Ltd

Competitors

Stock Name ⇩Market Cap ⇩Current Price ⇩High / Low ⇩Stock P/E ⇩Book Value ⇩Dividend Yield ⇩ROCE ⇩ROE ⇩Face Value ⇩
Lactose (India) Ltd 106 Cr. 84.2 137/76.021.9 49.60.00 %12.9 %9.69 % 10.0
MPS Pharmaa Ltd 3.15 Cr. 1.65 3.17/1.57 0.330.00 %9.79 %59.0 % 10.0
Gujarat Themis Biosyn Ltd 2,692 Cr. 247 479/22256.3 24.30.27 %27.3 %21.7 % 1.00
Gujarat Terce Laboratories Ltd 25.3 Cr. 32.5 68.4/29.0 10.10.00 %41.4 %14.6 % 10.0
Gujarat Inject (Kerala) Ltd 120 Cr. 82.1 82.1/17.0481 6.930.00 %13.5 %11.0 % 10.0
Industry Average19,815.15 Cr1,053.8453.84201.200.39%16.35%15.16%6.10

All Competitor Stocks of Mangalam Drugs and Organics Ltd

Quarterly Result

MetricDec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025
Sales 63.3291.1187.4681.5697.34102.2476.5379.9488.7173.0457.3549.5458.49
Expenses 56.8490.8790.9479.3790.3690.5468.3471.2579.9462.8861.8652.3759.96
Operating Profit 6.480.24-3.482.196.9811.708.198.698.7710.16-4.51-2.83-1.47
OPM % 10.23%0.26%-3.98%2.69%7.17%11.44%10.70%10.87%9.89%13.91%-7.86%-5.71%-2.51%
Other Income 0.130.290.020.030.000.050.020.140.130.210.000.030.11
Interest 3.223.433.413.243.313.953.753.673.494.034.045.034.05
Depreciation 2.882.753.423.733.623.863.873.973.934.614.384.534.37
Profit before tax 0.51-5.65-10.29-4.750.053.940.591.191.481.73-12.93-12.36-9.78
Tax % 15.69%-22.30%-7.29%-25.05%-920.00%9.90%-355.93%-125.21%5.41%90.75%6.19%-41.42%0.00%
Net Profit 0.43-4.39-9.54-3.560.503.552.682.691.400.15-13.73-7.25-9.78
EPS in Rs 0.27-2.77-6.03-2.250.322.241.691.700.880.09-8.67-4.58-6.18

Last Updated: February 5, 2026, 2:05 am

Quarterly Chart

Profit & Loss - Annual Report

Last Updated: February 24, 2026, 11:46 pm

MetricMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025TTM
Sales 123221295299269228282380451372369318238
Expenses 113200257252222218259327402347351282237
Operating Profit 1020384747102453492617361
OPM % 8%9%13%16%17%4%8%14%11%7%5%11%1%
Other Income 000-0101500000
Interest 10109101291091113141517
Depreciation 444577891011151618
Profit before tax -46243129-6640282-115-33
Tax % -22%-2%33%29%32%40%-32%29%29%43%-18%-39%
Net Profit -36162220-8828201-97-31
EPS in Rs -2.314.6611.1514.0812.57-5.075.2117.6712.420.80-5.724.37-19.34
Dividend Payout % 0%0%0%0%4%0%0%0%0%0%0%0%

Profit & Loss Yearly Chart

YoY Net Profit Growth

Year2014-20152015-20162016-20172017-20182018-20192019-20202020-20212021-20222022-20232023-20242024-2025
YoY Net Profit Growth (%)300.00%166.67%37.50%-9.09%-140.00%200.00%250.00%-28.57%-95.00%-1000.00%177.78%
Change in YoY Net Profit Growth (%)0.00%-133.33%-129.17%-46.59%-130.91%340.00%50.00%-278.57%-66.43%-905.00%1177.78%

Mangalam Drugs and Organics Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.

No data available for the compounded sales growth chart.

Balance Sheet

Last Updated: December 4, 2025, 1:37 am

MonthMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Sep 2025
Equity Capital 13131416161616161616161616
Reserves 10164770888088115135136127133112
Borrowings 777860666965527088891079695
Other Liabilities 25633838545075649011710811487
Total Liabilities 125170160190227211231264328358357359310
Fixed Assets 53535493102103101118135142147156152
CWIP 0050001669834
Investments 0002000000000
Other Assets 7211710095125107128140188206202201155
Total Assets 125170160190227211231264328358357359310

Reserves and Borrowings Chart

Cash Flow

MonthMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Cash from Operating Activity + 71422432522312826381243
Cash from Investing Activity + -2-4-11-39-16-9-7-31-27-22-18-19
Cash from Financing Activity + -5-10-11-3-9-11-2333-176-22
Net Cash Flow 01-00-010-11-1-02
Free Cash Flow 51011391224-4-216-623
CFO/OP 79%69%68%107%66%223%129%69%70%148%71%119%

Free Cash Flow

MonthMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Free Cash Flow-67.00-58.00-22.00-19.00-22.00-55.00-28.00-17.00-39.00-63.00-90.00-60.00

Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)

Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.

Free Cash Flow Chart

Financial Efficiency Indicators

MonthMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Debtor Days 887337456128525238462845
Inventory Days 170134856913217512185139200185303
Days Payable 97128373882771066365139124199
Cash Conversion Cycle 161798575111126677411210788148
Working Capital Days 292632193121102343381813
ROCE %6%16%29%31%25%2%11%27%18%6%1%8%

Financial Efficiency Indicators Chart

Share Holding Pattern

MonthMar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025
Promoters 50.31%50.31%50.31%50.31%50.31%50.31%50.30%50.30%50.30%50.30%50.30%35.64%
FIIs 0.10%0.10%0.10%0.10%0.26%0.21%0.11%0.11%0.47%0.53%0.11%0.13%
Public 49.59%49.58%49.59%49.59%49.42%49.47%49.58%49.58%49.23%49.16%49.57%64.22%
No. of Shareholders 17,94317,89017,97818,61019,17319,31219,50819,67919,69719,72819,88121,227

Shareholding Pattern Chart

No. of Shareholders

Mangalam Drugs and Organics Ltd: Intrinsic Value & Share Price Analysis - Shareholder trend analysis

This stock is not held by any mutual fund.

ROCE Trend

EPS Trend

Key Financial Ratios

MonthMar 25Mar 24
FaceValue 10.0010.00
Basic EPS (Rs.) 4.25-5.73
Diluted EPS (Rs.) 4.25-5.73
Cash EPS (Rs.) 14.743.52
Book Value[Excl.RevalReserv]/Share (Rs.) 94.1285.79
Book Value[Incl.RevalReserv]/Share (Rs.) 94.1285.79
Revenue From Operations / Share (Rs.) 201.05232.87
PBDIT / Share (Rs.) 22.9511.05
PBIT / Share (Rs.) 12.461.80
PBT / Share (Rs.) 3.02-7.00
Net Profit / Share (Rs.) 4.25-5.73
NP After MI And SOA / Share (Rs.) 4.25-5.73
PBDIT Margin (%) 11.414.74
PBIT Margin (%) 6.190.77
PBT Margin (%) 1.50-3.00
Net Profit Margin (%) 2.11-2.46
NP After MI And SOA Margin (%) 2.11-2.46
Return on Networth / Equity (%) 4.51-6.68
Return on Capital Employeed (%) 11.271.67
Return On Assets (%) 1.83-2.71
Long Term Debt / Equity (X) 0.060.09
Total Debt / Equity (X) 0.540.64
Asset Turnover Ratio (%) 0.900.00
Current Ratio (X) 1.041.07
Quick Ratio (X) 0.310.31
Inventory Turnover Ratio (X) 2.430.00
Interest Coverage Ratio (X) 2.431.26
Interest Coverage Ratio (Post Tax) (X) 1.450.34
Enterprise Value (Cr.) 196.06233.41
EV / Net Operating Revenue (X) 0.610.63
EV / EBITDA (X) 5.4013.34
MarketCap / Net Operating Revenue (X) 0.360.39
Price / BV (X) 0.781.08
Price / Net Operating Revenue (X) 0.360.39
EarningsYield 0.05-0.06

Profitability Ratios (%)

Liquidity Ratios

Liquidity Ratios (%)

Interest Coverage Ratios (%)

Valuation Ratios

About the Company - Qualitative Analysis

Mangalam Drugs and Organics Ltd. is a Public Limited Listed company incorporated on 18/04/1972 and has its registered office in the State of Maharashtra, India. Company's Corporate Identification Number(CIN) is L24230MH1972PLC116413 and registration number is 116413. Currently Company is involved in the business activities of Manufacture of pharmaceuticals, medicinal chemical and botanical products. Company's Total Operating Revenue is Rs. 318.23 Cr. and Equity Capital is Rs. 15.83 Cr. for the Year ended 31/03/2025.
INDUSTRYADDRESSCONTACT
PharmaceuticalsRupam Building, 3rd Floor, Mumbai Maharashtra 400001Contact not found
Management
NamePosition Held
Mr. Govardhan Murlidhar DhootChairman & Managing Director
Mr. Brijmohan Murlidhar DhootWhole Time Director
Mr. Praveen SaxenaIndependent Director
Mr. Rakesh Kishinchand MilwaniNon Exe.Non Ind.Director
Mr. Rukmesh Prabhukumar DhandhaniaIndependent Director
Mrs. Nidhi Shantanu MundadaIndependent Director

FAQ

What is the intrinsic value of Mangalam Drugs and Organics Ltd and is it undervalued?

As of 03 April 2026, Mangalam Drugs and Organics Ltd's intrinsic value is ₹83.41, which is 192.67% higher than the current market price of ₹28.50, suggesting the stock is undervalued. This is calculated using the PE ratio method factoring in ROE (4.71 %), book value (₹80.5), dividend yield (0.00 %), and 5-year EPS CAGR.

What is the current share price and 52-week range of Mangalam Drugs and Organics Ltd?

Mangalam Drugs and Organics Ltd is trading at ₹28.50 as of 03 April 2026, with a FY2026-2027 high of ₹95.0 and low of ₹22.7. The stock is currently near its 52-week low. Market cap stands at ₹45.1 Cr..

How does Mangalam Drugs and Organics Ltd's P/E ratio compare to its industry?

Mangalam Drugs and Organics Ltd has a P/E ratio of , which is below the industry average of 53.84. This is broadly in line with or below the industry average.

Is Mangalam Drugs and Organics Ltd financially healthy?

Key indicators for Mangalam Drugs and Organics Ltd: ROCE of 8.03 % is on the lower side compared to the industry average of 16.35%; ROE of 4.71 % is below ideal levels (industry average: 15.16%). Dividend yield is 0.00 %.

Is Mangalam Drugs and Organics Ltd profitable and how is the profit trend?

Mangalam Drugs and Organics Ltd reported a net profit of ₹7 Cr in Mar 2025 on revenue of ₹318 Cr. Compared to ₹20 Cr in Mar 2022, the net profit shows a declining trend.

Does Mangalam Drugs and Organics Ltd pay dividends?

Mangalam Drugs and Organics Ltd has a dividend yield of 0.00 % at the current price of ₹28.50. The company is currently not paying meaningful dividends.

Disclaimer: This article is for informational purposes only and should not be construed as financial advice. The author is not a SEBI registered financial advisor and does not have any vested interest in Mangalam Drugs and Organics Ltd. Investors are advised to conduct their own due diligence and consult with a financial professional before making any investment decisions. The information provided in this article is based on publicly available data and the author's analysis, but it may not be comprehensive or up-to-date. The author and getaka.co.in are not responsible for any errors or omissions in the content. This article is not intended to promote any particular investment strategy or recommendation, and readers should consult with their own financial advisors before making any investment decisions. Data Source: NSE
Explore Industry-wise Stock Analysis Reports